Abstract
Management of superficial aspergillosis is a major challenge owing to the frequent relapses and treatment failure, which may pose a potential risk, thereby gradually developing resistant species. Therefore, necessitating the development of new antifungals with higher potency should be considered as alternative strategies for efficient management of infections. We aimed to investigate the susceptibility of Aspergillus isolates toward a novel triazole, efinaconazole, in comparison with various classes of antifungal drugs. Antifungal susceptibility testing was performed according to the Clinical and Laboratory Standards Institute M38-A2 guidelines. Efinaconazole exhibited poor activity against mutant A. fumigatus strains, A. niger sensu stricto, and A. tubingensis with GM MIC values of 3.62, 1.62, and 2 μg/ml, respectively; however, surprisingly, it efficiently inhibited the growth of A. terreus sensu stricto, followed by wild-type A. fumigatus and A. flavus with GM MIC values of 0.29, 0.42, and 0.52 μg/ml, respectively. Presumably, efinaconazole is inefficient in aspergillosis treatment due to the low susceptibility of A. niger sensu stricto, A. tubingensis, and mutant A. fumigatus; however, it may be effective in treating superficial aspergillosis caused by wild-type A. fumigatus, A. terreus sensu stricto, and A. flavus. Further studies are needed to determine how these findings may translate into in vivo efficacy.
References
Badali H, Vaezi A, Haghani I, Yazdanparast SA, Hedayati MT, Mousavi B, et al. Environmental study of azole-resistant Aspergillus fumigatus with TR34/L98H mutations in the cyp51A gene in Iran. Mycoses. 2013;56:659–63. https://doi.org/10.1111/myc.12089.
Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63:e1–60. https://doi.org/10.1093/cid/ciw326.
Lestrade PP, Meis JF, Arends JP, van der Beek MT, de Brauwer E, van Dijk K, et al. Diagnosis and management of aspergillosis in the Netherlands: a national survey. Mycoses. 2016;59:101–7. https://doi.org/10.1111/myc.12440.
Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50:1091–100. https://doi.org/10.1086/651263.
Bongomin F, Batac CR, Richardson MD, Denning DW. A review of onychomycosis due to Aspergillus species. Mycopathologia. 2018;183:485–93. https://doi.org/10.1007/s11046-017-0222-9.
Satish HS, Viswanatha B, Manjuladevi M. A clinical study of otomycosis. IOSR J Dent Med Sci. 2013;5(2):57–62.
Gharaghani M, Seifi Z, Zarei Mahmoudabadi A. Otomycosis in iran: a review. Mycopathologia. 2015;179(5–6):415–24. https://doi.org/10.1007/s11046-015-9864-7.
Hagiwara S, Tamura T, Satoh K, Kamewada H, Nakano M, Shinden S, Yamaguchi H, Makimura K. The molecular identification and antifungal susceptibilities of aspergillus species causing otomycosis in Tochigi, Japan. Mycopathologia. 2019;184(1):13–21. https://doi.org/10.1007/s11046-018-0299-9.
Ghannoum M, Isham N. Fungal nail infections (onychomycosis): a never-ending story? PLoS Pathog. 2014;10:e1004105. https://doi.org/10.1371/journal.ppat.1004105.
Tosti A, Piraccini BM, Lorenzi S. Onychomycosis caused by nondermatophytic molds: clinical features and response to treatment of 59 cases. J Am Acad Dermatol. 2000;42:217–24. https://doi.org/10.1016/S0190-9622(00)90129-4.
Ahmadi B, Hashemi SJ, Zaini F, Shidfar MR, Moazeni M, Mousavi B, et al. A case of onychomycosis caused by Aspergillus candidus. Med Mycol Case Rep. 2012;1:45–8. https://doi.org/10.1016/j.mmcr.2012.06.003.
Zarei F, Mirhendi H, Fakhim H, Geramishoar M. The first case of onychomycosis due to Aspergillus uvarum (section Nigri). Mycoses. 2015;58(4):239–42. https://doi.org/10.1111/myc.12304.
Anwar K, Gohar MS. Otomycosis; clinical features, predisposing factors and treatment implications. Pak J Med Sci. 2014;30(3):564–7.
Khanna D, Bharti S. Luliconazole for the treatment of fungal infections: an evidence-based review. Core Evid. 2014;9:113–24. https://doi.org/10.2147/ce.s49629.
Liu C, Shi C, Mao F, Xu Y, Liu J, Wei B, et al. Discovery of new imidazole derivatives containing the 2, 4-dienone motif with broad-spectrum antifungal and antibacterial activity. Molecules. 2014;19:15653–72. https://doi.org/10.3390/molecules191015653.
Poulakos M, Grace Y, Machin JD, Dorval E. Efinaconazole and tavaborole: emerging antifungal alternatives for the topical treatment of onychomycosis. J Pharm Pract. 2017;30:245–55. https://doi.org/10.1177/0897190016630904.
Bhatt V, Pillai R. Efinaconazole topical solution, 10%: formulation development program of a new topical treatment of toenail onychomycosis. J Pharm Sci. 2015;104:2177–82. https://doi.org/10.1002/jps.24459.
Pipner SR, Scher RK. Efinaconazole 10% topical solution for the topical treatment of onychomycosis of the toenail. Expert Rev Clin Pharmacol. 2015;8:719–31.
Uchida K, Nishiyama Y, Tanaka T, Yamaguchi H. In vitro activity of novel imidazole antifungal agent NND-502 against Malassezia species. Int J Antimicrob Agents. 2003;21:234–8.
Noguchi H, Matsumoto T, Hiruma M, Asao K, Hirose M, Fukushima S, et al. Topical efinaconazole: a promising therapeutic medication for tinea unguium. J Dermatol. 2018;45:1225–8. https://doi.org/10.1111/1346-8138.14575.
Abastabar M, Rahimi N, Meis JF, Aslani N, Khodavaisy S, Nabili M, et al. Potent activities of novel imidazoles lanoconazole and luliconazole against a collection of azole-resistant and-susceptible Aspergillus fumigatus strains. Antimicrob Agents Chemother. 2016;60:6916–9. https://doi.org/10.1128/aac.01193-16.
Baghi N, Shokohi T, Badali H, Makimura K, Rezaei-Matehkolaei A, Abdollahi M, et al. In vitro activity of new azoles luliconazole and lanoconazole compared with ten other antifungal drugs against clinical dermatophyte isolates. Med Mycol. 2016;54:757–63. https://doi.org/10.1093/mmy/myw016.
Shokoohi GR, Badali H, Mirhendi H, Ansari S, Rezaei-Matehkolaei A, Ahmadi B, et al. In vitro activities of luliconazole, lanoconazole, and efinaconazole compared with those of five antifungal drugs against melanized fungi and relatives. Antimicrob Agents Chemother. 2017;61(11):24. https://doi.org/10.1128/aac.00635-17.
Badali H, Fakhim H, Zarei F, Nabili M, Vaezi A, Poorzad N, et al. In vitro activities of five antifungal drugs against opportunistic agents of Aspergillus Nigri complex. Mycopathologia. 2016;181:235–40. https://doi.org/10.1007/s11046-015-9968-0.
Vaezi A, Fakhim H, Arastehfar A, Shokohi T, Hedayati MT, Khodavaisy S, et al. In vitro antifungal activity of amphotericin B and 11 comparators against Aspergillus terreus species complex. Mycoses. 2018;61:134–42. https://doi.org/10.1111/myc.12716.
Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A2. Wayne: Clinical and Laboratory Standards Institute; 2008.
Monti D, Mazzantini D, Tampucci S, Vecchione A, Celandroni F, Burgalassi S, et al. Ciclopirox and efinaconazole transungual permeation, antifungal activity, and proficiency to induce resistance in Trichophyton rubrum. Antimicrob Agents Chemother. 2019; https://doi.org/10.1128/aac.00442-19.
Tupaki-Sreepurna A, Jishnu B, Thanneru V, Sharma S, Gopi A, Sundaram M, et al. An assessment of in vitro antifungal activities of efinaconazole and itraconazole against common non-dermatophyte fungi causing onychomycosis. J Fungi. 2017;3(2):20. https://doi.org/10.3390/jof3020020.
Hur MS, Park M, Jung WH, Lee YW. Evaluation of drug susceptibility test for Efinaconazole compared with conventional antifungal agents. Mycoses. 2019;62:291–7. https://doi.org/10.1111/myc.12870.
Rezaei-Matehkolaei A, Khodavaisy S, Alshahni MM, Tamura T, Satoh K, Abastabar M, et al. In vitro antifungal activity of novel triazole efinaconazole and five comparators against dermatophyte isolates. Antimicrob Agents Chemother. 2018;62(5):e2423. https://doi.org/10.1128/aac.02423-17.
Abastabar M, Al-Hatmi AMS, Vafaei Moghaddam M, de Hoog GS, Haghani I, Aghili SR, et al. Potent activities of luliconazole, lanoconazole, and eight comparators against molecularly characterized Fusarium species. Antimicrob Agents Chemother. 2018;62(5):e00009–18. https://doi.org/10.1128/aac.00009-18.
Ghannoum MA, Long L, Kim HG, Cirino AJ, Miller AR, Mallefet P. Efficacy of terbinafine compared to lanoconazole and luliconazole in the topical treatment of dermatophytosis in a guinea pig model. Med Mycol. 2010;48:491–7. https://doi.org/10.3109/13693780903373811.
Acknowledgements
We are grateful to our colleagues within the Invasive Fungi Research Center, Mazandaran University of Medical Sciences, Sari, Iran, for fruitful discussion.
Funding
This study was financially supported by a grant from the National Institutes for Medical Research Development (NIMAD) (Grant No. 977223) and Mazandaran University of Medical Sciences (Sari, Iran) (Grant No. 3211) that we gratefully acknowledge.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
No potential conflicts of interest. The authors alone are responsible for the content and writing of the paper.
Ethical Approval
Ethical permission for this study was approved by the Ethical Committee of Mazandaran University of Medical Sciences, Sari, Iran (nr. IR.MAZUMS.REC.1397.3211).
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Handling editor: Ahmed Sarah.
Rights and permissions
About this article
Cite this article
Taheri Rizi, Z., Abastabar, M., Fakhim, H. et al. Antifungal Activity of a Novel Triazole, Efinaconazole and Nine Comparators against 354 Molecularly Identified Aspergillus Isolates. Mycopathologia 185, 357–365 (2020). https://doi.org/10.1007/s11046-020-00434-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11046-020-00434-z